Novartis AG (NVS)
Pre-Market:
| Previous Close | 84.17 |
| Open | 84.85 |
| Bid | 83.93 x 900 |
| Ask | 84.00 x 800 |
| Day's Range | 84.65 - 85.25 |
| 52 Week Range | 79.09 - 95.17 |
| Volume | |
| Avg. Volume | 2,450,674 |
| Market Cap | 189.011B |
| Beta (5Y Monthly) | 0.48 |
| PE Ratio (TTM) | 7.90 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.33 (4.10%) |
| Ex-Dividend Date | Mar 08, 2022 |
| 1y Target Est | N/A |
- GlobeNewswire
New Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy
First-line tislelizumab plus chemotherapy showed median overall survival of 17.2 months versus 10.6 months for chemotherapy and reduced risk of death by 34% in patients with advanced esophageal squamous cell carcinoma1 Statistically significant survival benefit with tislelizumab plus chemotherapy was observed regardless of PD-L1 status and consistent across all patient subgroups1 Novartis to discuss results of multi-regional RATIONALE 306 study, the seventh positive Phase III trial readout for t
- GlobeNewswire
Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia
With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least two prior tyrosine kinase inhibitor treatments1 Positive opinion based on data from pivotal Phase III ASCEMBL trial, showing a near doubling in major molecular response rate for patients treated with Scemblix® (asciminib) vs. Bosulif®* (bosutinib) (25.5% vs. 13.2%) and more than three times lower d
- GlobeNewswire
Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
Novartis endorses the Kigali Declaration on neglected tropical diseases, pledging USD 250 million to advance R&D of new treatments against NTDs and malaria over five yearsCommitment includes USD 100 million to advance R&D for Chagas disease, leishmaniasis, dengue and cryptosporidiosis, and USD 150 million for next-generation antimalarials and a new formulation for babies under 5kg with malariaAround the world, 1.7 billion people suffer from NTDs1, and there are 241 million cases of malaria2 Base
